Skip to content
Screener

D&A at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$179M+162%
BioLife Solutions logo
BioLife SolutionsBLFS
$157K+138%
Revvity logo
RevvityRVTY
$105.06M+7.8%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$67.29M-43.7%

Segments

By segment

See full
Multiomics$2.65M-34.2%

Other financials

Income statement

See full
Revenue$161.2M+12.0%
Gross profit$72.4M+9.0%
Operating income-$4.2M-126%
Net income$2.5M+105%
EPS (diluted)$0.05+105%

Balance sheet

See full
Cash & equivalents$70.8M
Total debt$54.0M
Total equity$1.5B-9.7%
Total assets$1.9B

Cash flow

See full
Operating cash flow$1.4M-94.4%
CapEx$6.6M-38.7%
Free cash flow$6.1M-12.7%

Valuation

See full
Market cap$1.48B+15.1%
Enterprise value$1.46B
P/S2.4×+0.3×

Profitability

See full
Gross margin40%-1.0pp
Operating margin-31.6%-59.7pp
Net margin-20%+1.5pp
FCF margin8.6%

Returns & leverage

See full
Return on equity-7.7%
Debt / equity
Current ratio2.5×

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The source filing: Azenta’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:09 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054295

FAQ

What is Azenta's D&A?
Azenta (AZTA) reported D&A of $13.58M in Q2 2026.
How has Azenta's D&A changed year-over-year?
Azenta's D&A decreased by 7.8% year-over-year, from $14.72M to $13.58M.
What is the long-term trend for Azenta's D&A?
Over 4 years (2021 to 2025), Azenta's D&A has grown at a -1.6% compound annual growth rate (CAGR), from $65.33M to $61.21M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Azenta's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude